{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.44","value":"12.63"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG001","spread":"NA","value":"13.93"},{"groupId":"OG002","spread":"57.56","value":"16.32"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG003","spread":"NA","value":"20.39"},{"groupId":"OG004","spread":"58.96","value":"27.08"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG005","spread":"NA","value":"25.29"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG006","spread":"NA","value":"78.31"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG007","spread":"NA","value":"63.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"43.62","value":"22.32"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG003","spread":"NA","value":"31.40"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG004","spread":"NA","value":"31.43"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG005","spread":"NA","value":"33.23"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG007","spread":"NA","value":"58.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose","reportingStatus":"POSTED","timeFrame":"Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)","title":"Dose Escalation Part: AUC0-inf of Free MMAE","type":"SECONDARY","unitOfMeasure":"day*ng/mL"}